Protean Congratulates Intern Luke Rathbun on His Research, Published in Oncotarget
Protean congratulates intern Luke Rathbun on his research, published in Oncotarget
Oncotarget – May 4th 2023
A research paper was published in Oncotarget titled, "Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma", written by Luke A. Rathbun, Anthony M. Magliocco and Anil K. Bamezai
Abstract:
The human Lymphocyte antigen-6 (LY6) gene family has recently gained interest for its possible role in tumor progression. We have carried out in silico analyses of all known LY6 gene expression and amplification in different cancers using TNMplot and cBioportal. We also have analyzed patient survival by Kaplan-Meier plotter after mining the TCGA database. We report that upregulated expression of many LY6 genes is associated with poor survival in uterine corpus endometrial carcinoma (UCEC) cancer patients. Importantly, the expression of several LY6 genes is elevated in UCEC when compared to the expression in normal uterine tissue. For example, LY6K expression is 8.25× higher in UCEC compared to normal uterine tissue, and this high expression is associated with poor survival with a hazard ratio of 2.42 (p-value = 0.0032). Therefore, some LY6 gene products may serve as tumor-associated antigens in UCEC, biomarkers for UCEC detection, and possibly targets for directing UCEC patient therapy. Further analysis of tumor-specific expression of LY6 gene family members and LY6-triggered signaling pathways is needed to uncover the function of LY6 proteins and their ability to endow tumor survival and poor prognosis in UCEC patients.
For further information, please contact:
Anthony Magliocco MD
CEO & President of Protean BioDiagnostics
Email: info@proteanbiodx.com
Phone: 1 (813) 817 2042
About Protean BioDiagnostics
Protean is an innovative diagnostic company developing new approaches to improving precision medicine including inventing digital pathology tools to improve cancer screening and detection.
Protean MAPS™ is the only unique precision medicine system that provides easy access to advanced comprehensive laboratory diagnostic tests and easy to understand reports along with telemedicine support. Protean’s mission is to accelerate and bring optimized precision care to all cancer patients regardless of where they live.